User login
WASHINGTON – Peramivir, an investigational single-dose antiviral drug to treat influenza, could deliver multiple benefits for physicians and patients alike, Dr. Richard J. Whitley predicted.
At the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Washington, Dr. Whitley co-presented an analysis of phase II and phase III clinical trials that show the safety and efficacy of peramivir, which is currently under review by the U.S. Food and Drug Administration. Dr. Whitley is distinguished professor of pediatrics and microbiology at the University of Alabama at Birmingham.
In a video interview, Dr. Whitley discusses what this new flu drug could mean for physicians and patients, when the drug might be approved by the FDA, and why a new flu pandemic could be coming sooner rather than later.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – Peramivir, an investigational single-dose antiviral drug to treat influenza, could deliver multiple benefits for physicians and patients alike, Dr. Richard J. Whitley predicted.
At the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Washington, Dr. Whitley co-presented an analysis of phase II and phase III clinical trials that show the safety and efficacy of peramivir, which is currently under review by the U.S. Food and Drug Administration. Dr. Whitley is distinguished professor of pediatrics and microbiology at the University of Alabama at Birmingham.
In a video interview, Dr. Whitley discusses what this new flu drug could mean for physicians and patients, when the drug might be approved by the FDA, and why a new flu pandemic could be coming sooner rather than later.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – Peramivir, an investigational single-dose antiviral drug to treat influenza, could deliver multiple benefits for physicians and patients alike, Dr. Richard J. Whitley predicted.
At the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Washington, Dr. Whitley co-presented an analysis of phase II and phase III clinical trials that show the safety and efficacy of peramivir, which is currently under review by the U.S. Food and Drug Administration. Dr. Whitley is distinguished professor of pediatrics and microbiology at the University of Alabama at Birmingham.
In a video interview, Dr. Whitley discusses what this new flu drug could mean for physicians and patients, when the drug might be approved by the FDA, and why a new flu pandemic could be coming sooner rather than later.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT ICAAC 2014
